Alnylam Pharmaceuticals
ALNY
#562
Rank
NZ$63.20 B
Marketcap
$488.31
Share price
-3.35%
Change (1 day)
92.72%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$7.14. In 2022 the company made an earnings per share (EPS) of -$16.15 a decrease over its 2021 EPS that were of -$12.51.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-59.41%
2022-$16.1529.03%
2021-$12.51-3.36%
2020-$12.95-8.48%
2019-$14.157.67%
2018-$13.1439.74%
2017-$9.4012.94%
2016-$8.3338.84%
2015-$6.00-32.88%
2014-$8.93259.44%
2013-$2.49-31.25%
2012-$3.6252.94%
2011-$2.3630.77%
2010-$1.81-8.77%
2009-$1.9878.13%
2008-$1.11-70.78%
2007-$3.8199.09%
2006-$1.91-43.88%
2005-$3.41-82.33%
2004-$19.28-59.23%
2003-$47.29

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.95-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$64.93-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.61 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.47-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.94-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.50-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.53-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.48-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel